Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Finished Goods (2019 - 2025)

Outset Medical (OM) has disclosed Finished Goods for 7 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • Quarterly Finished Goods fell 44.71% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, down 44.71% year-over-year, with the annual reading at $13.1 million for FY2025, 44.71% down from the prior year.
  • Finished Goods for Q4 2025 was $13.1 million at Outset Medical, down from $15.8 million in the prior quarter.
  • The five-year high for Finished Goods was $26.4 million in Q2 2024, with the low at $6.1 million in Q1 2021.
  • Average Finished Goods over 5 years is $17.8 million, with a median of $17.6 million recorded in 2022.
  • The sharpest move saw Finished Goods skyrocketed 300.0% in 2021, then tumbled 46.17% in 2023.
  • Over 5 years, Finished Goods stood at $15.0 million in 2021, then skyrocketed by 44.95% to $21.8 million in 2022, then increased by 0.06% to $21.8 million in 2023, then rose by 8.86% to $23.7 million in 2024, then plummeted by 44.71% to $13.1 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $13.1 million, $15.8 million, and $17.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.